HEB : Summary for Hemispherx BioPharma, Inc. Comm - Yahoo Finance

U.S. Markets close in 3 hrs 45 mins

Hemispherx Biopharma, Inc. (HEB)


NYSE MKT - NYSE MKT Real Time Price. Currency in USD
Add to watchlist
0.87+0.05 (+5.45%)
As of 12:15 PM EST. Market open.
People also watch:
GNBTCVMBCRXCTICVICL
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.82
Open0.89
Bid0.85 x 100
Ask0.87 x 100
Day's Range0.85 - 0.89
52 Week Range0.72 - 2.64
Volume60,507
Avg. Volume74,371
Market Cap20.97M
Beta-0.99
PE Ratio (TTM)-1.92
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Marketwired6 days ago

    Crystal Research Associates, LLC Issues Executive Informational Overview on Hemispherx Biopharma, Inc.

    Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview® on Hemispherx Biopharma, Inc. . The full 60-page report is available on Crystal Research Associates' ...

  • Capital Cube14 days ago

    ETFs with exposure to Hemispherx Biopharma, Inc. : November 23, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016
    Capital Cube16 days ago

    Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016

    Categories: Yahoo Finance Get free summary analysis Hemispherx Biopharma, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Hemispherx Biopharma, Inc. – Sarepta Therapeutics, Inc., Baxter International Inc., Gilead Sciences, Inc., GlaxoSmithKline plc Sponsored ADR, Merck & Co., Inc., Astrazeneca PLC Sponsored ADR, Valeant Pharmaceuticals International ... Read more (Read more...)